• In mid-June 2026, FMC Corporation and Corteva, Inc. announced a co-exclusive supply and license agreement for FMC’s rimisoxafen herbicide technology across North and South American corn and soybean markets, with Corteva making an initial US$200,000,000 prepurchase payment and first sales targeted by the end of the decade, subject to regulatory approvals.
• The agreement gives FMC wider access to Corteva’s corn and soybean distribution channels while preserving FMC’s ownership of rimisoxafen, potentially enhancing the value of its crop protection pipeline beyond this single molecule.
• Now we’ll examine how FMC’s long-term rimisoxafen partnership with Corteva could influence its existing investment narrative and future cash flow repair.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

FMC Investment Narrative Recap

To own FMC today, you need to believe its crop protection pipeline and cost program can repair cash flows and support gradual deleveraging after steep share price losses. The rimisoxafen deal with Corteva brings an upfront US$200,000,000 payment and broader market access, but its commercial impact is back-end loaded, so the key near term catalyst remains execution on 2026 revenue and margin guidance, while elevated leverage and weak recent profitability still look like the central risk.

The rimisoxafen agreement sits alongside FMC’s recent debt refinancing, including the US$1,200,000,000 8.000% Senior Secured Notes due 2031 issued in early June 2026. Together, these moves highlight how product partnerships and balance sheet work are intertwined with the core catalyst of restoring earnings quality and meeting 2026 guidance, while also underscoring refinancing and interest coverage as areas for investors to monitor more closely.

Yet behind the promise of new herbicide income, investors should be aware that concentrated product and regulatory risk could still...

FMC's narrative projects $4.0 billion revenue and $286.1 million earnings by 2029. This requires 5.3% yearly revenue growth and a $2.8 billion earnings increase from -$2.5 billion today.

Uncover how FMC's forecasts yield a $17.53 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts paint a far harsher picture, assuming only about US$3,900,000,000 of revenue and roughly US$272,000,000 of earnings by 2029, so if you are weighing this new Corteva tie up against concerns about regulatory pressure and slower growth, it is worth recognizing how differently FMC’s prospects can be viewed.

Explore 5 other fair value estimates on FMC - why the stock might be worth just $13.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your FMC research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free FMC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FMC's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.